We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

97 hedge funds and large institutions have $171M invested in Antares Pharma, Inc. in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 47 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

174% more call options, than puts

Call options by funds: $1.01M | Put options by funds: $368K

161% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 18

11% more funds holding

Funds holding: 87 → 97 (+10)

10% less capital invested

Capital invested by funds: $190M → $171M (-$18.9M)

Holders
97
Holders Change
+10
Holders Change %
+11.49%
% of All Funds
3.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
47
Reduced
18
Closed
4
Calls
$1.01M
Puts
$368K
Net Calls
+$640K
Net Calls Change
+$2.16M

Top Buyers

Rank Fund Capital Flow
1
HCM
Harvey Capital Management
Florida
+$2.31M
2
BFA
BlackRock Fund Advisors
California
+$1.67M
3
BIT
BlackRock Institutional Trust
California
+$1.01M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$964K
5
WHI
William Harris Investors
Illinois
+$546K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.1M
2
DM
Deerfield Management
New York
-$3.26M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$944K
4
UOC
UBS O'Connor
Illinois
-$913K
5
TCIM
TIAA CREF Investment Management
New York
-$666K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$35.1M -$3.26M -746,881 -8%
O
2
OrbiMed
New York
$17.7M -$21.1M -4,834,000 -53%
BIT
3
BlackRock Institutional Trust
California
$15M +$1.01M +230,510 +7%
Vanguard Group
4
Vanguard Group
Pennsylvania
$13.8M +$276K +63,081 +2%
BFA
5
BlackRock Fund Advisors
California
$13M +$1.67M +382,914 +14%
State Street
6
State Street
Massachusetts
$7.93M +$333K +76,267 +4%
WHI
7
William Harris Investors
Illinois
$7.4M +$546K +125,000 +7%
Northern Trust
8
Northern Trust
Illinois
$6.41M +$275K +63,063 +4%
Allianz Asset Management
9
Allianz Asset Management
Germany
$6.13M +$216K +49,471 +3%
TAM
10
THB Asset Management
Connecticut
$4.54M -$126K -28,900 -3%
UBS AM
11
UBS AM
Illinois
$3.72M +$131K +30,100 +3%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$2.98M +$406K +92,863 +14%
KCM
13
Kingdon Capital Management
New York
$2.33M +$328K +75,000 +15%
HCM
14
Harvey Capital Management
Florida
$2.14M +$2.31M +528,000 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.06M +$109K +24,901 +5%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$1.99M -$944K -216,200 -31%
TCIM
17
TIAA CREF Investment Management
New York
$1.85M -$666K -152,496 -25%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$1.49M +$180K +41,200 +13%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$1.4M +$964K +220,611 +179%
BIM
20
BlackRock Investment Management
Delaware
$1.3M +$88.3K +20,209 +7%
Charles Schwab
21
Charles Schwab
California
$1.17M +$15K +3,445 +1%
AC
22
Avenir Corporation
Virginia
$1.13M – – –
Invesco
23
Invesco
Georgia
$1.13M – – –
UOC
24
UBS O'Connor
Illinois
$1.08M -$913K -209,000 -44%
AllianceBernstein
25
AllianceBernstein
Tennessee
$1M +$64.3K +14,725 +6%
1
2 3 4

ATRS Hedge Fund Activity: Q3 2013 in Review

97 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2013, worth a combined $171M — down 9.9% from $190M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ATRS positions and 4 closed out — a net gain of 10 holders — while 47 added to existing stakes and 18 trimmed.

The largest buyer was Harvey Capital Management, opening a new position worth an estimated $2.31M. The largest seller was OrbiMed, cutting an estimated $21.1M.

  • 97 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2013, up from 87 in Q2 2013.
  • Funds reported $171M of Antares Pharma, Inc. stock for Q3 2013, down 9.9% quarter-over-quarter.
  • 14 funds opened new Antares Pharma, Inc. positions in Q3 2013 and 4 closed out, a net change of +10 holders.
  • The largest Antares Pharma, Inc. buyer in Q3 2013 was Harvey Capital Management, an estimated $2.31M added.
  • The largest Antares Pharma, Inc. seller in Q3 2013 was OrbiMed, an estimated $21.1M sold.

Based on aggregated 13F filings for Q3 2013.